研究者業績
  1. 研究者検索結果一覧
  2. 小林 欣夫

小林 欣夫

コバヤシ ヨシオ  (Yoshio Kobayashi)

基本情報

所属
千葉大学 大学院医学研究院循環器内科学 教授
学位
博士(医学）(千葉大学)
J-GLOBAL ID
200901031812437900
researchmap会員ID
5000068706

研究キーワード

 1

研究分野

 1

経歴

 2

論文

 853
  • 細谷 裕一, 近藤 祐介, 小野 仁, 鳴海 頌子, 吉野 裕, 龍崎 智子, 千葉 俊典, 菅原 暢文, 北川 真理, 伊藤 竜, 仲野 美代, 梶山 貴嗣, 中野 正博, 小林 欣夫
    日本循環器学会学術集会抄録集 87回 CO5-1 2023年3月  
  • 鳴海 頌子, 近藤 祐介, 中野 正博, 梶山 貴嗣, 仲野 美代, 伊藤 竜, 北川 真理, 菅原 暢文, 千葉 俊典, 龍崎 智子, 吉野 裕, 小野 仁, 細谷 裕一, 小林 欣夫
    日本循環器学会学術集会抄録集 87回 CP19-7 2023年3月  
  • 鳴海 頌子, 近藤 祐介, 中野 正博, 梶山 貴嗣, 仲野 美代, 伊藤 竜, 北川 真理, 菅原 暢文, 千葉 俊典, 龍崎 智子, 吉野 裕, 小野 仁, 細谷 裕一, 小林 欣夫
    日本循環器学会学術集会抄録集 87回 CP24-5 2023年3月  
  • 岩花 東吾, 加藤 央隼, 小野 亮平, 青木 薫子, 岡田 将, 小林 欣夫
    日本循環器学会学術集会抄録集 87回 PJ072-4 2023年3月  
  • 小野 亮平, 岩花 東吾, 青木 薫子, 加藤 央隼, 岡田 将, 小林 欣夫
    日本循環器学会学術集会抄録集 87回 PJ079-6 2023年3月  
  • 加藤 央隼, 岩花 東吾, 青木 薫子, 小野 亮平, 小林 欣夫
    日本循環器学会学術集会抄録集 87回 PJ082-4 2023年3月  
  • 小野 亮平, 岩花 東吾, 青木 薫子, 加藤 央隼, 岡田 将, 小林 欣夫
    日本循環器学会学術集会抄録集 87回 PJ121-5 2023年3月  
  • 青木 薫子, 岩花 東吾, 小野 亮平, 加藤 央隼, 岡田 将, 小林 欣夫
    日本循環器学会学術集会抄録集 87回 CROJ14-2 2023年3月  
  • 加藤 央隼, 岩花 東吾, 青木 薫子, 小野 亮平, 小林 欣夫
    日本循環器学会学術集会抄録集 87回 CROJ15-4 2023年3月  
  • 與子田 一輝, 佐々木 晴香, 高岡 浩之, 青木 秀平, 鈴木 克也, 八島 聡美, 高橋 愛, 木下 真己子, 江口 紀子, 鎌田 知子, 川崎 健治, 高梨 秀一郎, 松宮 護郎, 小林 欣夫, 松下 一之
    日本循環器学会学術集会抄録集 87回 CO1-1 2023年3月  
  • Takanori Sato, Yuichi Saito, Hideki Kitahara, Yoshio Kobayashi
    Life (Basel, Switzerland) 13(3) 2023年2月24日  
    The GRACE risk score is established to predict thrombotic events in patients with acute coronary syndrome (ACS). Although thrombotic events including myocardial infarction after ACS are mainly attributable to vulnerable plaque formation, whether the GRACE score correlates with coronary lipid-rich plaque is unclear. A total of 54 patients with ACS undergoing primary percutaneous coronary intervention under near-infrared spectroscopy intravascular ultrasound (NIRS-IVUS) guidance were included in a prospective manner. Patients were divided into two groups according to the median of the GRACE risk score. Coronary lipid plaques in the target vessel were assessed by NIRS-IVUS with lipid core burden index (LCBI) and a maximum LCBI in 4 mm (maxLCBI4mm). The receiver operating characteristics (ROC) curve analysis was performed based on the major adverse cardiovascular events as an exploratory analysis. The GRACE risk score was significantly and positively correlated with LCBI (r = 0.31, p = 0.03) and maxLCBI4mm (r = 0.38, p = 0.006). LCBI (111.7 ± 85.7 vs. 169.0 ± 83.5, p = 0.02) and maxLCBI4mm (428.5 ± 227.1 vs. 600.6 ± 227.7, p = 0.009) in the target vessel were significantly higher in the high GRACE risk score group than their counterpart. In the ROC curve analysis, LCBI and maxLCBI4mm were predictive for clinical events. In conclusion, the higher GRACE risk score may serve as a discriminator of risk comprising more lipid-rich plaques as an underlying mechanism of an increased risk of thrombotic events after ACS. In patients with ACS, the higher GRACE risk score was significantly and modestly associated with greater coronary lipid plaques in the target vessel.
  • Ryohei Ono, Togo Iwahana, Michiko Daimon, Hirotoshi Kato, Kaoruko Aoki, Kaori Abe, Yoshio Kobayashi
    BMJ case reports 16(2) 2023年2月2日  
  • Masafumi Sugawara, Kajiyama Takatsugu, Yusuke Kondo, Michiko Watanabe, Goro Matsumiya, Yoshio Kobayashi
    HeartRhythm case reports 9(2) 80-83 2023年2月  
  • Kenichi Sakakura, Yoshiaki Ito, Yoshisato Shibata, Atsunori Okamura, Yoshifumi Kashima, Shigeru Nakamura, Yuji Hamazaki, Junya Ako, Hiroyoshi Yokoi, Yoshio Kobayashi, Yuji Ikari
    Cardiovascular intervention and therapeutics 2023年1月16日  
    The Task Force on Rotational Atherectomy of the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT) proposed the expert consensus document to summarize the techniques and evidences regarding rotational atherectomy (RA) in 2020. Because the revascularization strategy to severely calcified lesions is the hottest topic in contemporary percutaneous coronary intervention (PCI), many evidences related to RA have been published since 2020. Latest advancements have been incorporated in this updated expert consensus document.
  • Yuichi Saito, Yoshio Kobayashi
    Cardiovascular Intervention and Therapeutics 2023年1月7日  
  • Hideki Kitahara, Kazuya Tateishi, Yuki Shiko, Yusuke Inaba, Yoshio Kobayashi, Takahiro Inoue
    PloS one 18(10) e0293937 2023年  
    [This corrects the article DOI: 10.1371/journal.pone.0272140.].
  • Shinjo Sonoda, Kiyoshi Hibi, Hiroyuki Okura, Kenichi Fujii, Koichi Node, Yoshio Kobayashi, Junko Honye
    Cardiovascular intervention and therapeutics 38(1) 1-7 2023年1月  
    There are 3 main reasons to promote the practical application of IVUS during PCI. First reason is to understand the mechanism of vessel dilatation. Even if angiographic stenoses are similar, their pathophysiologies are different. It is important to understand what can happen by dilating coronary artery with balloon/stent, and to develop a strategy to achieve the maximum effect. Second reason is to anticipate possible complications and to reduce them in advance. In that case, we can deal with it as calmly as possible. Third reason is to validate the PCI performed. This should lead to further improvements of the procedures, which in turn will lead to improved short- and long-term prognosis. Then, high-quality PCI could be possible. This review summarizes the standard usage of IVUS in routine clinical practice and the use of IVUS in specific situations, especially complex lesions.
  • Shinjo Sonoda, Kiyoshi Hibi, Hiroyuki Okura, Kenichi Fujii, Koichi Node, Yoshio Kobayashi, Junko Honye
    Cardiovascular intervention and therapeutics 38(1) 8-8 2023年1月  
  • Daichi Yamashita, Yuichi Saito, Takanori Sato, Tadahiro Matsumoto, Sakuramaru Suzuki, Kan Saito, Shinichi Wakabayashi, Hideki Kitahara, Koichi Sano, Yoshio Kobayashi
    Internal Medicine 2023年  
  • Hiroki Goto, Yuichi Saito, Tadahiro Matsumoto, Takanori Sato, Daichi Yamashita, Sakuramaru Suzuki, Shinichi Wakabayashi, Hideki Kitahara, Koichi Sano, Yoshio Kobayashi
    Journal of Atherosclerosis and Thrombosis 2023年  
  • Ryohei Ono, Togo Iwahana, Yoshio Kobayashi
    European heart journal. Case reports 7(1) ytac473 2023年1月  
  • Ryohei Ono, Togo Iwahana, Hirotoshi Kato, Yoshio Kobayashi
    Clinical case reports 11(1) e6851 2023年1月  
    The patients after heart transplantation usually present resting tachycardia, a slower increase in heart rate (HR) at the onset of exercise, a blunted chronotropic response to exercise in general, maximal HR being attained in the recovery period rather than at peak exercise, and a slower decline in HR after exercise.
  • Masato Kanda, Toshio Nagai, Naomichi Kondo, Katsuhisa Matsuura, Hiroshi Akazawa, Issei Komuro, Yoshio Kobayashi
    Cell Transplantation 32 096368972311740-096368972311740 2023年1月  
    Many studies have explored cardiac progenitor cell (CPC) therapy for heart disease. However, optimal scaffolds are needed to ensure the engraftment of transplanted cells. We produced a three-dimensional hydrogel scaffold (CPC-PRGmx) in which high-viability CPCs were cultured for up to 8 weeks. CPC-PRGmx contained an RGD peptide-conjugated self-assembling peptide with insulin-like growth factor-1 (IGF-1). Immediately after creating myocardial infarction (MI), we transplanted CPC-PRGmx into the pericardial space on to the surface of the MI area. Four weeks after transplantation, red fluorescent protein-expressing CPCs and in situ hybridization analysis in sex-mismatched transplantations revealed the engraftment of CPCs in the transplanted scaffold (which was cellularized with host cells). The average scar area of the CPC-PRGmx-treated group was significantly smaller than that of the non-treated group (CPC-PRGmx-treated group = 46 ± 5.1%, non-treated MI group = 59 ± 4.5%; p < 0.05). Echocardiography showed that the transplantation of CPC-PRGmx improved cardiac function and attenuated cardiac remodeling after MI. The transplantation of CPCs-PRGmx promoted angiogenesis and inhibited apoptosis, compared to the untreated MI group. CPCs-PRGmx secreted more vascular endothelial growth factor than CPCs cultured on two-dimensional dishes. Genetic fate mapping revealed that CPC-PRGmx-treated mice had more regenerated cardiomyocytes than non-treated mice in the MI area (CPC-PRGmx-treated group = 0.98 ± 0.25%, non-treated MI group = 0.25 ± 0.04%; p < 0.05). Our findings reveal the therapeutic potential of epicardial-transplanted CPC-PRGmx. Its beneficial effects may be mediated by sustainable cell viability, paracrine function, and the enhancement of de novo cardiomyogenesis.
  • Yuichi Saito, Taku Inohara, Shun Kohsaka, Hideki Wada, Itaru Takamisawa, Kyohei Yamaji, Tetsuya Amano, Yoshio Kobayashi, Ken Kozuma
    American Heart Journal 2023年1月  
  • Yuichi Saito, Osamu Hashimoto, Takashi Nakayama, Haruka Sasaki, Keita Yumoto, Susumu Oshima, Tetsuya Tobaru, Shunichi Kushida, Junji Kanda, Yoshiaki Sakai, Shinichi Okino, Shigeru Fukuzawa, Akihiko Abiko, Tomonori Itoh, Yoshitake Nakamura, Takahiro Nakashima, Satoshi Yasuda, Kenji Goto, Hideo Takebayashi, Takashi Oshitomi, Tomohiro Sakamoto, Sunao Kojima, Yoritaka Otsuka, Toshiharu Himi, Yusuke Inagaki, Junichi Yamaguchi, Kenichi Hagiya, Mamoru Nanasato, Yoshio Kobayashi
    International Journal of Cardiology 371 49-53 2023年1月  
  • Hideki Kitahara, Hiraku Kumamaru, Shun Kohsaka, Daichi Yamashita, Tomoyoshi Kanda, Kaoru Mastuura, Kazuo Shimamura, Goro Matsumiya, Yoshio Kobayashi
    Circulation journal : official journal of the Japanese Circulation Society 2022年12月27日  
    BACKGROUND: Limited data are available for clinical outcomes in patients who underwent urgent or emergency transcatheter aortic valve implantation (TAVI). This study investigated in-hospital and 1-year outcomes and explored prognostic covariates in urgent/emergency TAVI using nationwide registry data.Methods and Results: Among 26,775 patients who underwent TAVI between August 2013 and December 2019, 25,495 with 1-year follow-up information were analyzed in this study. Baseline and procedural characteristics, as well as clinical adverse events, were compared between the urgent/emergency and elective TAVI groups. The primary outcome was all-cause mortality within 1 year after TAVI. Multivariable Cox regression models were constructed to identify independent predictors after urgent or emergency TAVI. Urgent or emergency TAVI was performed in 578 (2.3%) patients. The Society of Thoracic Surgeons score was significantly higher in the urgent/emergency than elective TAVI group (13.3% vs. 6.0%; P<0.001). Device success rate was comparable between the 2 groups. All-cause death-free survival within 1 year was lower in the urgent/emergency than elective TAVI group (77.2% vs. 92.2%; log rank P<0.001). Malignancy, albumin and creatinine concentrations, ejection fraction, and mean pressure gradient were associated with 1-year mortality in the urgent/emergency TAVI group. CONCLUSIONS: Despite higher surgical risk and more comorbidities, the procedure was successfully performed in patients undergoing urgent/emergency TAVI, although it should be noted that prognosis was worse than for elective TAVI.
  • Yusei Nishikawa, Hiroyuki Takaoka, Tomonori Kanaeda, Haruhiro Takahira, Sakuramaru Suzuki, Shuhei Aoki, Hiroki Goto, Katsuya Suzuki, Satomi Yashima, Manami Takahashi, Makiko Kinoshita, Haruka Sasaki, Noriko Suzuki-Eguchi, Koichi Sano, Yoshio Kobayashi
    Heart and vessels 38(5) 721-730 2022年12月19日  
    Recently, myocardial extracellular volume (ECV) analysis has been measurable on computed tomography (CT) using new software. We evaluated the use of cardiac CT to estimate the myocardial ECV of left ventricular (LV) myocardium (LVM) to predict reverse remodeling (RR) in cases of atrial fibrillation (AF) after catheter ablation (CA). Four hundred and seven patients underwent CA for AF in our institution from April 2014 to Feb 2021. Of these, 33 patients (8%) with an LVEF ≤ 50% and who had undergone CT were included in our study. We estimated the LVM ECV using commercial software to analyze the CT data. RR was defined as an improvement in LVEF to > 50% after CA. LVEF increased to > 50% in 24 patients (73%) after CA. In all 24 patients, LVM ECV, LV end-diastolic and end-systolic volumes (LVEDV and LVESV), and the n-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) were significantly lower than in the other nine patients (P = 0.0037, 0.0273, 0.0443, and < 0.0001). On receiver operating characteristic curve analysis, the best cut-off of ECV, LVEDV, LVESV and NT-proBNP for the prediction of RR were 37.73%, 120 mL, 82 mL, and 1267 pg/mL, respectively. We newly defined the ENL (ECV, NT-proBNP, and LVEDV) score as the summed score for the presence or absence (1 or 0; maximum score = 3) of ECV, NT-proBNP, and LVEDV values less than or equal to each best cut-off value, and found that this score gave the highest area under the curve for the prediction of RR (0.9583, P < 0.0001). The ENL score may be useful for predicting RR in patients with AF undergoing CA.
  • Tatsuro Yamazaki, Yuichi Saito, Daichi Yamashita, Hideki Kitahara, Yoshio Kobayashi
    Heart and Vessels 2022年12月9日  
  • Ami Niwano, Haruka Sasaki, Hiroyuki Takaoka, Kenji Kawasaki, Kentaro Atarashi, Jun-Ichiro Ikeda, Goro Matsumiya, Kazuyuki Matsushita, Yoshio Kobayashi
    Journal of cardiology cases 26(6) 404-406 2022年12月  
    UNLABELLED: Papillary fibroelastoma (PFE) is a rare, slow-growing cardiac tumor. We encountered an 80-year-old man with PFE accidentally revealed by transthoracic echocardiography (TTE) to evaluate cardiac function before a non-cardiac operation. A 10-mm mass lesion adhered to the anterior papillary muscle of the left ventricle, which had not been detected with TTE performed nine months before. Emergency cardiac surgery to remove the mass was performed, and the mass was diagnosed as a PFE. The PFE grew to 10 mm in a maximum of 9 months; to our knowledge, this is the fastest growth of PFE in the left ventricle reported to date. LEARNING OBJECTIVE: Papillary fibroelastoma (PFE) is a rare, slow-growing cardiac tumor. The surgical indication of PFE is sometimes controversial. The rapid growth of PFE might be considered as a criterion for surgery because this might result in the rapid progression of symptoms and complications.
  • Yusuke Kondo, Takatsugu Kajiyama, Toshinori Chiba, Masahiro Nakano, Yoshio Kobayashi
    IJC Heart &amp; Vasculature 43 101137-101137 2022年12月  
  • Kazunari Asada, Yuichi Saito, Takanori Sato, Tadahiro Matsumoto, Daichi Yamashita, Sakuramaru Suzuki, Shinichi Wakabayashi, Hideki Kitahara, Koichi Sano, Yoshio Kobayashi
    Circulation Journal 2022年11月23日  
  • 高岡 浩之, 大門 道子, 佐々木 晴香, 青木 秀平, 小林 欣夫
    Heart View 26(12) 191-201 2022年11月  
    ＜文献概要＞▼心電図は心筋疾患の鑑別に際し初期段階で施行される検査であり,各心筋症における特徴的異常所見の理解が必要である。▼CTやMRIなどの画像診断の進歩は目覚ましく,心電図を踏まえた適切な心筋疾患診断のため,その継続的な知識のupdateが重要である。
  • Takanori Sato, Yuichi Saito, Sakuramaru Suzuki, Tadahiro Matsumoto, Daichi Yamashita, Kan Saito, Shinichi Wakabayashi, Hideki Kitahara, Koichi Sano, Yoshio Kobayashi
    Life 12(10) 1672-1672 2022年10月21日  
    Among patients with acute myocardial infarction (MI) complicated by cardiogenic shock (CS), in-hospital mortality remains high. In the present study, we aimed to identify factors associated with clinical outcomes of acute MI patients with CS in a contemporary setting. A total of 1102 patients with acute MI undergoing primary percutaneous coronary intervention were included, among whom 196 (17.8%) were complicated by CS. The primary outcome was all-cause death during hospitalization, and factors associated with in-hospital mortality were explored in patients with acute MI and CS. Of the 196 patients with acute MI complicated by CS, 77 (39.3%) died during hospitalization. The rates of non-ST-segment elevation MI (NSTEMI) (33.8% vs. 19.3%, p = 0.02) and culprit lesion in the left main or left anterior descending coronary artery (68.8% vs. 47.9%, p = 0.004) were higher, while left ventricular ejection fraction (LVEF) was lower (24.4 ± 11.7% vs. 39.7 ± 13.8%, p &lt; 0.001) in non-survivors than in survivors. Multivariable analysis identified NSTEMI presentation and lower LVEF as independent predictors of in-hospital death. In conclusion, NSTEMI and low LVEF were identified as factors associated with higher in-hospital mortality. The identification of even higher-risk subsets and targeted therapeutic strategies may be warranted to improve survival of patients with acute MI and CS.
  • Takashi Hiraga, Yuichi Saito, Kazuya Tateishi, Naoto Mori, Takayo Murase, Takashi Nakamura, Seigo Akari, Kan Saito, Hideki Kitahara, Yoshio Kobayashi
    Medicina 58(10) 1423-1423 2022年10月10日  
    Background and Objectives: Although previous studies showed that an activity of xanthine oxidoreductase (XOR), a rate-limiting enzyme in purine metabolism, beyond the serum uric acid level, was associated with the development of coronary artery disease (CAD), the underlying mechanisms are unclear. Because endothelial dysfunction and a greater blood pressure (BP) variability may play a role, we investigated the relations among the endothelial function, XOR, and BP variability. Materials and Methods: This was a post-hoc study using pooled data of patients with a stable CAD from two prospective investigations, in which the systemic endothelial function was assessed with the reactive hyperemia index (RHI) and the XOR activity was measured. The BP variability was evaluated using BP measurements during the three- and four-day hospitalization. Results: A total of 106 patients with a stable CAD undergoing a percutaneous coronary intervention were included. Of the 106 patients, 46 (43.4%) had a systemic endothelial dysfunction (RHI &lt; 1.67). The multivariable analysis identified a higher body mass index (BMI), female gender, and diabetes as factors associated with an endothelial dysfunction. A higher BMI was also related to an elevated XOR activity, in addition to current smoking. No significant correlation was observed between the RHI and XOR activity. Similarly, the in-hospital BP variability was associated with neither the endothelial function nor XOR. Conclusions: Among patients with a stable CAD, several factors were identified as being associated with a systemic endothelial dysfunction or an elevated XOR activity. However, no direct relations between the endothelial function, XOR, and BP variability were found.
  • Kan Saito, Hideki Kitahara, Takaaki Mastuoka, Naoto Mori, Kazuya Tateishi, Yoshihide Fujimoto, Yoshio Kobayashi
    Heart and vessels 37(10) 1701-1709 2022年10月  
    BACKGROUND: This study aims to clarify whether myocardial bridge (MB) could influence atherosclerotic plaque characteristics assessed using near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS) imaging. METHODS: One hundred and sixteen patients who underwent percutaneous coronary intervention (PCI) using NIRS-IVUS imaging were included. MB was defined as an echo-lucent band surrounding left anterior descending artery (LAD). In MB patients, LAD was divided into three segments: proximal, MB, and distal segments. In non-MB patients, corresponding three segments were defined based on the average length of the above segments. Segmental maximum plaque burden and lipid content derived from NIRS-IVUS imaging in the section of maximum plaque burden were evaluated in each segment. Lipid content of atherosclerotic plaque was evaluated as lipid core burden index (LCBI) and maxLCBI4mm. LCBI is the fraction of pixels indicating lipid within a region multiplied by 1000, and the maximum LCBI in any 4-mm region was defined as maxLCBI4mm. RESULTS: MB was identified in 42 patients. MB was not associated with maximum plaque burden in proximal segment. LCBI and maxLCBI4mm were significantly lower in patients with MB than those without in proximal segment. Multivariable analysis demonstrated both MB and maximum plaque burden in proximal segment to be independent predictors of LCBI in proximal segment. CONCLUSIONS: Lipid content of atherosclerotic plaque assessed by NIRS-IVUS imaging was significantly smaller in patients with MB than those without. MB could be considered as a predictor of lipid content of atherosclerotic plaque when assessed by NIRS-IVUS imaging.
  • 小野 亮平, 王 斯睿, 岩花 東吾, 劉 浩, 小林 欣夫
    脈管学 62(Suppl.) S130-S130 2022年10月  
  • 岩花 東吾, 加藤 央隼, 小野 亮平, 青木 薫子, 岡田 将, 黄野 皓木, 渡邉 倫子, 松宮 護郎, 小林 欣夫
    人工臓器 51(2) S-151 2022年10月  
  • Kazuya Tateishi, Yuichi Saito, Tatsuro Yamazaki, Hideki Kitahara, Yoshio Kobayashi
    Diabetes Epidemiology and Management 8 100104-100104 2022年10月  
  • 後藤 宏樹, 高岡 浩之, 山岸 嘉希, 坂井 上之, 村山 大知, 松本 浩史, 大門 道子, 佐々木 晴香, 青木 秀平, 鈴木 克也, 高橋 愛, 八島 聡美, 木下 真己子, 江口 紀子, 金枝 朋宜, 小林 欣夫
    循環器内科 92(3) 242-250 2022年9月  
  • 浅田 一成, 高岡 浩之, 後藤 宏樹, 鈴木 櫻丸, 高平 青洋, 高橋 愛, 八島 聡美, 木下 真己子, 佐々木 晴香, 江口 紀子, 金枝 朋宜, 小林 欣夫, 桃井 瑞生
    日本心臓病学会学術集会抄録 70回 S33-4 2022年9月  
  • 青木 秀平, 高岡 浩之, 浅田 一成, 後藤 宏樹, 高橋 愛, 八島 聡美, 木下 真己子, 江口 紀子, 佐々木 晴香, 金枝 朋宜, 小林 欣夫, 齋藤 千紘
    日本心臓病学会学術集会抄録 70回 S27-1 2022年9月  
  • 近藤 祐介, 龍崎 智子, 仲野 美代, 中野 正博, 梶山 貴嗣, 伊藤 竜, 北川 真理, 菅原 暢文, 千葉 俊典, 小林 欣夫
    日本心臓病学会学術集会抄録 70回 O-1 2022年9月  
  • 龍崎 智子, 近藤 祐介, 中野 正博, 梶山 貴嗣, 仲野 美代, 伊藤 竜, 北川 真理, 菅原 暢文, 千葉 俊典, 吉野 裕, 鳴海 頌子, 小林 欣夫
    日本心臓病学会学術集会抄録 70回 O-2 2022年9月  
  • Yuichi Saito, Atsushi Tanaka, Yuji Koide, Hisako Yoshida, Daigaku Uchida, Kazuo Matsunaga, Naoto Yokota, Chikara Ueyama, Yoshio Kobayashi, Koichi Node
    RMD Open 8(2) e002505-e002505 2022年9月  
    Objectives Although uric acid lowering therapies, including xanthine oxidase (XO) inhibition, may reduce the absolute level of blood pressure (BP), the effect of XO inhibition on BP variability is largely unknown. The aim of the present analysis was to evaluate the impact of febuxostat, an XO inhibitor, on BP variability in a randomised trial setting. Methods This was a subanalysis of the PRIZE Study, a randomised trial to evaluate the potential effect of febuxostat on carotid intima–media thickness progression. Patients with hyperuricemia and carotid plaques were randomly assigned to the febuxostat or control group. During a 24-month period, office BP and pulse rate (PR) were measured ≥3 times. BP and PR variabilities were assessed with SD and coefficient of variation (CV). The effect of febuxostat on BP and PR variabilities was adjusted with age, sex and baseline BP or PR, expressed with 95% CIs. Results A total of 472 patients were included into the present subanalysis. During the 24-month follow-up period, the febuxostat group had a significantly lower adjusted mean systolic BP (128.4 (126.8–130.0) vs 130.7 (129.1–132.2) mm Hg, p=0.04) and CV of systolic BP (7.4 (6.7–8.0) vs 8.2 (7.6–8.8), p=0.04) than the control group. Adjusted SD of PR was also lower in the febuxostat group than their counterpart (5.95 (4.93–6.97) vs 7.33 (6.32–8.33), p=0.04). Conclusion XO inhibition with febuxostat was associated with reduced visit-to-visit BP variability as well as reduced PR variability in patients with hyperuricemia and carotid plaques. Trial registration numbers University Hospital Medical Information Network Clinical Trial Registry (UMIN000012911 and UMIN000041322).
  • 近藤 祐介, 龍崎 智子, 仲野 美代, 中野 正博, 梶山 貴嗣, 伊藤 竜, 北川 真理, 菅原 暢文, 千葉 俊典, 小林 欣夫
    日本心臓病学会学術集会抄録 70回 O-1 2022年9月  
  • 龍崎 智子, 近藤 祐介, 中野 正博, 梶山 貴嗣, 仲野 美代, 伊藤 竜, 北川 真理, 菅原 暢文, 千葉 俊典, 吉野 裕, 鳴海 頌子, 小林 欣夫
    日本心臓病学会学術集会抄録 70回 O-2 2022年9月  
  • Sakuramaru Suzuki, Yuichi Saito, Daichi Yamashita, Tadahiro Matsumoto, Takanori Sato, Shinichi Wakabayashi, Hideki Kitahara, Koichi Sano, Yoshio Kobayashi
    Heart, Lung and Circulation 31(9) 1228-1233 2022年9月  
  • Takahiro Kobayashi, Hideki Kitahara, Ken Kato, Yuichi Saito, Yoshio Kobayashi
    Circulation journal : official journal of the Japanese Circulation Society 2022年8月27日  
    BACKGROUND: Dialysis patients have strong intracoronary calcification, accelerated by secondary hyperparathyroidism as well as atherosclerosis. We evaluated the association of intact parathyroid hormone (iPTH) level with intracoronary calcification evaluated by intravascular ultrasound (IVUS), and its impact on both stent expansion after percutaneous coronary intervention (PCI) and long-term clinical outcomes, in dialysis patients with coronary artery disease (CAD).Methods and Results: A total of 116 patients on dialysis, who underwent PCI with IVUS guidance between March 2012 and December 2020, were enrolled. Patients were divided into 2 groups based on their median iPTH level. The degree of intracoronary calcification was evaluated by calcification score using grayscale IVUS in the target lesions. Preprocedural calcification scores were significantly higher in the high iPTH group compared with the low iPTH group (2.9±1.1 vs. 2.1±0.7, P<0.001). After PCI, the high iPTH group had a significantly lower stent expansion index (0.6±0.2 vs. 0.7±0.1, P<0.001) and stent symmetry index (0.5±0.1 vs. 0.7±0.1, P<0.001) compared with the low iPTH group. The incidence of major adverse cardiac or cerebrovascular events within 3 years was significantly higher in the high iPTH group (log-rank P<0.05). CONCLUSIONS: High iPTH level is likely to increase intracoronary calcification, and cause inadequate stent expansion, which may be associated with increased risk of future adverse events in dialysis patients with CAD requiring PCI.
  • Shuhei Aoki, Hiroyuki Takaoka, Ryo Ito, Hiroki Ikeuchi, Noriko Suzuki-Eguchi, Haruka Sasaki, Makiko Kinoshita, Manami Takahashi, Satomi Yashima, Katsuya Suzuki, Hiroki Goto, Hideki Kitahara, Junji Moriya, Goro Matsumiya, Yoshio Kobayashi
    Internal medicine (Tokyo, Japan) 62(7) 1017-1022 2022年8月20日  
    We treated a female patient known to have a double-chambered right ventricle (DCRV) who presented with symptoms of an acute myocardial infarction (AMI). Emergent coronary artery catheterization revealed acute right coronary artery (RCA) occlusion and proximal left anterior descending (LAD) stenosis. We performed percutaneous coronary intervention (PCI) for the RCA occlusion. Right heart catheterization revealed a pressure gradient across the mid-RV of 58 mmHg. Computed tomography and magnetic resonance imaging revealed no other congenital cardiac abnormalities. She underwent surgical repair of the RV stenosis and coronary artery bypass surgery for LAD stenosis.
  • Yutaka Yoshino, Hiroyuki Takaoka, Hiromichi Oishi, Shuhei Aoki, Hiroki Goto, Manami Takahashi, Satomi Yashima, Noriko Suzuki-Eguchi, Haruka Sasaki, Makiko Kinoshita, Hideki Kitahara, Yoshio Kobayashi
    Circulation journal : official journal of the Japanese Circulation Society 86(12) 2040-2040 2022年8月20日  

MISC

 393
  • Yoshiyasu Minami, Junya Ako, Kenichi Tsujita, Hiroyoshi Yokoi, Yuji Ikari, Yoshihiro Morino, Yoshio Kobayashi, Ken Kozuma
    Cardiovascular Intervention and Therapeutics 39(3) 223-233 2024年7月  
    Abstract: Non-culprit lesion-related coronary events are a significant concern in patients with coronary artery disease (CAD) undergoing coronary intervention. Since several studies using intra-coronary imaging modalities have reported a high prevalence of vulnerable plaques in non-culprit lesions at the initial coronary event, the immediate stabilization of these plaques by intensive pharmacological regimens may contribute to the reduction in the adverse events. Although current treatment guidelines recommend the titration of statin and other drugs to attain the treatment goal of low-density lipoprotein cholesterol (LDL-C) level in patients with CAD, the early prescription of strong LDL-C lowering drugs with more intensive regimen may further reduce the incidence of recurrent cardiovascular events. In fact, several studies with intensive regimen have demonstrated a higher percentage of patients with the attainment of LDL-C treatment goal in the early phase following discharge. In addition to many imaging studies showing plaque stabilization by LDL-C lowering drugs, several recent reports have shown the efficacy of early statin and proprotein convertase subtilisin/kexin type 9 inhibitors on the immediate stabilization of non-culprit coronary plaques. To raise awareness regarding this important concept of immediate plaque stabilization and subsequent reduction in the incidence of recurrent coronary events, the term ‘Drug Intervention’ has been introduced and gradually applied in the clinical field, although a clear definition is lacking. The main target of this concept is patients with acute coronary syndrome as a higher prevalence of vulnerable plaques in non-culprit lesions in addition to the worse clinical outcomes has been reported in recent imaging studies. In this article, we discuss the backgrounds and the concept of drug intervention. Graphical Abstract: (Figure presented.)
  • 與子田一輝, 與子田一輝, 佐々木晴香, 佐々木晴香, 佐々木晴香, 高岡浩之, 鎌田知子, 川崎健治, 江口紀子, 江口紀子, 江口紀子, 小林欣夫, 松下一之, 松下一之
    超音波医学 Supplement 51 2024年  
  • YASHIMA Satomi, TAKAOKA Hiroyuki, TAKAHASHI Manami, KINOSHITA Makiko, AOKI Shuhei, KOBAYASHI Yoshio
    日本循環器学会学術集会(Web) 87th 2023年  
  • KINOSHITA Makiko, TAKAOKA Hiroyuki, AOKI Shuhei, SUZUKI Katsuya, TAKAHASHI Manami, YASHIMA Satomi, SASAKI Haruka, SUZUKI Noriko, KONDO Yusuke, KOBAYASHI Yoshio
    日本循環器学会学術集会(Web) 87th 2023年  
  • 木下真己子, 岡田将, 青木秀平, 鈴木克也, 八島聡美, 佐々木晴香, 鈴木紀子, 高岡浩之, 小林欣夫
    超音波医学 Supplement 50 2023年  
もっとみる

所属学協会

 10
もっとみる

共同研究・競争的資金等の研究課題

 6
もっとみる
一覧へ戻る